Minoxidil: topical vs. oral, and why it often pairs with finasteride

Minoxidil was originally developed in the 1970s as an oral medication for severe high blood pressure. It is a potent vasodilator — it relaxes blood vessel walls and lowers blood pressure dramatically — and was approved for that purpose in 1979 under the brand name Loniten.

During clinical use, an unexpected side effect emerged: many patients on oral minoxidil grew thicker, longer hair on their scalp, face, arms, and legs. The phenomenon was so consistent that it raised a question — could the same mechanism that was producing unwanted body hair as a side effect also be useful as a deliberate hair loss treatment?

Researchers reformulated minoxidil as a topical solution and tested it for androgenetic alopecia. The results were positive, and topical minoxidil was approved by the FDA in 1988 as the first medical treatment for male pattern hair loss. (Finasteride would follow nine years later.)

Forty years on, minoxidil is still standard care, the mechanism is still incompletely understood, and the unexpected origin story is a useful reminder that some of the most useful drugs in medicine have come from paying attention to side effects rather than chasing target hypotheses.

The exact mechanism of minoxidil in hair growth is still not fully understood, which is unusual for a medication that has been used for decades. The current best explanation has several pieces.

Vasodilation. Minoxidil dilates blood vessels in the scalp, increasing blood flow to hair follicles. More blood flow means more oxygen and nutrients, which appears to support active follicle function.

Anagen prolongation. The hair growth cycle has three phases: anagen (active growth, lasting years), catagen (a brief transition phase), and telogen (rest, lasting weeks before the hair sheds). Minoxidil appears to extend the anagen phase, keeping follicles in active growth longer than they would otherwise stay.

Telogen-to-anagen conversion. Minoxidil also seems to push some resting (telogen) follicles back into active growth (anagen) earlier than they otherwise would. This is thought to be the mechanism behind the "minoxidil shed" — when treatment starts, telogen hairs are pushed out faster to make way for new anagen growth, producing a temporary spike in shedding before regrowth becomes visible.

Sulfation in the scalp. For topical minoxidil to work, it must be converted in the scalp by an enzyme called sulfotransferase to its active form, minoxidil sulfate. Some people have low scalp sulfotransferase activity and are partial or full non-responders to topical minoxidil — they may benefit more from the oral formulation, which bypasses this step by using systemic conversion.

Unlike finasteride, minoxidil does not affect DHT or any other androgen pathway. It works downstream, on the follicle itself, which is why it can complement finasteride rather than overlapping with it.

Topical minoxidil is FDA-approved in 2% and 5% formulations and is sold over the counter in the U.S. The 5% formulation (originally branded as Rogaine) is the one with the most efficacy data in men. It is applied to the scalp once or twice daily, depending on the formulation.

There are two main vehicles: liquid solution (a propylene glycol base that some users find irritating) and foam (which tends to be better tolerated and easier to apply without dripping). The active ingredient is the same; the difference is the carrier. Most dermatologists recommend the foam for new users.

Application is straightforward — about 1 mL of solution or a half-capful of foam, massaged into a dry scalp on the thinning areas, twice daily for the liquid or once daily for the foam. The vehicle dries within minutes. Wash hands afterward.

The two biggest practical issues with topical minoxidil are compliance and partial response. Twice-daily application for an indefinite period is hard to sustain. And as mentioned, some men have low scalp sulfotransferase activity and respond poorly to the topical form regardless of how diligently they apply it. There is a sulfotransferase test available, but it is not widely used; most clinicians prefer to give topical minoxidil a fair trial of 6–12 months and then assess.

Topical minoxidil has minimal systemic absorption when used as directed, which is why it has a clean safety profile. Local side effects include scalp irritation, dryness, itching, and occasional contact dermatitis (often from the propylene glycol vehicle in the liquid). Switching to the foam usually resolves vehicle-related issues.

Low-dose oral minoxidil has become one of the most discussed developments in hair loss treatment in the last several years. The doses used for hair loss (typically 1.25–5 mg daily) are dramatically lower than the doses originally used for hypertension (10–40 mg daily), and at these lower doses the cardiovascular effects are minimal in most patients.

The case for oral minoxidil is straightforward. It bypasses the sulfotransferase issue that limits topical efficacy in some users. It is taken once daily as a pill, which is dramatically easier to comply with than twice-daily scalp application. And the published case series and uncontrolled studies have shown efficacy at least comparable to topical, often better in patients who responded poorly to topical.

The trade-off is systemic exposure. Oral minoxidil can cause fluid retention (swelling of the legs, hands, or face), increased body hair growth (the original side effect that started this whole story), occasional mild blood pressure changes, and rarely, fast heart rate or palpitations. Most of these effects are dose-dependent and are uncommon at the 1.25 mg starting dose. Some patients are titrated up slowly to 2.5 or 5 mg as needed.

Oral minoxidil for hair loss is prescribed off-label in the U.S. — there is no FDA approval for this indication, and the prescribing relies on the published case series and clinical experience rather than randomized trials. Larger placebo-controlled trials are underway and will likely solidify (or refine) the dosing guidance over the next few years.

One of the most important things to understand before starting any minoxidil regimen is the initial shed. In the first 2–8 weeks of treatment, many patients notice an increase in hair shedding — sometimes a worrying increase. This is not a sign that the medication is making things worse. It is the expected effect of pushing telogen hairs out faster to make way for new anagen growth.

The shed typically peaks in the first few weeks, then slows, and is usually replaced by new growth over the following months. It is uncomfortable, especially for someone who started treatment because they were already losing hair, but it is a temporary phase that most patients pass through.

Patients who quit minoxidil during the initial shed never see the regrowth — and then conclude that the medication did not work. The honest framing for new users is: expect things to look the same or possibly slightly worse for the first 2–3 months, and judge results at month 6 and beyond.

Visible regrowth typically begins around month 4–6, with continued improvement through month 12. Like finasteride, the benefit plateaus and is then maintained as long as you keep using the medication.

Finasteride reduces the hormonal driver of hair loss by lowering DHT. Minoxidil stimulates the follicles directly through a different mechanism. The two drugs address different parts of the same problem, and combining them produces better outcomes than either alone in essentially every head-to-head trial that has been done.

A typical combination protocol for a man with moderate androgenetic alopecia might be: oral finasteride 1 mg daily, plus topical minoxidil 5% foam once daily, plus possibly low-dose oral minoxidil if topical alone is insufficient. This combination is sometimes called "the standard of care" for men who want maximum benefit and are willing to accept the modest side effect profile of both medications.

For men who want a single medication, finasteride alone has the stronger effect on halting progression — it addresses the root cause. Minoxidil alone is the right choice for men who cannot or prefer not to take an antiandrogen, but it does not stop the underlying disease process.

For maximum effect, the combination is the answer. The cost is modest (both drugs are generic and inexpensive in their oral forms), the application is no more burdensome than either alone, and the results are visibly better in trial photographs than monotherapy.

Topical minoxidil side effects are mostly local — scalp irritation, dryness, contact dermatitis. Switching from liquid to foam usually resolves vehicle-related issues. Systemic side effects from topical minoxidil are uncommon when used as directed.

Oral minoxidil side effects are more systemic and include fluid retention, increased body or facial hair growth, mild blood pressure changes, and rarely, more serious cardiovascular effects. Patients on oral minoxidil should have a baseline blood pressure check and follow-up monitoring, especially during dose escalation.

Both forms should be used with caution in patients with significant cardiovascular disease, especially heart failure, where fluid retention could worsen the underlying condition. Patients on other antihypertensive medications should coordinate with their prescribing clinician to avoid additive blood pressure effects.

Pregnancy and breastfeeding: minoxidil is generally not recommended. Like finasteride, it should not be handled or used by women who are pregnant or could become pregnant.

Children and adolescents: minoxidil is not typically used in patients under 18. Adolescent androgenetic alopecia is unusual and warrants a different evaluation before assuming standard treatment is appropriate.

The single most reliable predictor of long-term satisfaction with hair loss treatment is whether the user set realistic expectations at the start. Minoxidil and finasteride are excellent at slowing or halting progression, modestly effective at thickening existing hair, and only sometimes capable of meaningful regrowth in areas that have already substantially thinned. Patients who start treatment expecting to fully reverse years of loss are usually disappointed even when the medications are working as well as they realistically can.

A more useful framing: the goal of treatment is not to look like a 22-year-old. The goal is to look like the version of you who did not lose more hair this year. Compared to the trajectory you would be on without treatment, the gap grows every year you stay on the regimen. The benefit is cumulative and compounds over time.

How to actually measure progress. The mirror is a terrible measurement tool because you see your hair every day and small daily changes are invisible. Memory is also unreliable — patients who are six months into treatment routinely misremember how thin their hair was at baseline. The two tools that work are standardized photography and counting.

Standardized photography. Take a photo at the start of treatment. Use the same lighting, same camera, same angle, and same hair length. Keep your head in the same orientation. Take a follow-up photo at month 6 and another at month 12 under identical conditions. The side-by-side comparison is what reveals the actual change — without it, you are guessing.

Counting hairs in the drain. This is unreliable on a daily basis but useful as a long-term trend. Hair shedding varies normally between 50 and 100 hairs per day, and shedding rates fluctuate with stress, season, and the hair growth cycle. A rough sense of "I am shedding noticeably less than I was six months ago" is useful; a precise daily count is noise.

The other thing nobody tells you: patients who consistently follow the regimen and take the photos almost always see results that surprise them at the 12-month mark. Patients who quit at month 4 because "it is not working" never get the comparison data. The single biggest predictor of perceived success is whether you stayed on the protocol long enough to see the comparison photos.